Trial Profile
PREDICTIVE MARKERS OF THE EFFICACY IN METASTATIC COLORECTAL TUMOR TREATED WITH CETUXIMAB - PHASE 2 STUDY.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2011
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Pharmacogenomic; Therapeutic Use
- 30 Jul 2011 New trial record